Takeda Pharmaceutical Co Stock Current Valuation
| TAK Stock | USD 13.86 0.24 1.76% |
Valuation analysis of Takeda Pharmaceutical helps investors to measure Takeda Pharmaceutical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is expected to rise to 18.12 this year. Enterprise Value Multiple is expected to rise to 18.12 this year. Fundamental drivers impacting Takeda Pharmaceutical's valuation include:
Price Book 0.9443 | Enterprise Value 70.2 B | Enterprise Value Ebitda 9.0763 | Price Sales 0.0095 | Forward PE 15.528 |
Undervalued
Today
Please note that Takeda Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Takeda Pharmaceutical is based on 3 months time horizon. Increasing Takeda Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Takeda Pharmaceutical's intrinsic value may or may not be the same as its current market price of 13.86, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.86 | Real 15.08 | Target 19.12 | Hype 13.61 | Naive 13.65 |
The intrinsic value of Takeda Pharmaceutical's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Takeda Pharmaceutical's stock price.
Estimating the potential upside or downside of Takeda Pharmaceutical Co helps investors to forecast how Takeda stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Takeda Pharmaceutical more accurately as focusing exclusively on Takeda Pharmaceutical's fundamentals will not take into account other important factors: Takeda Pharmaceutical Co Company Current Valuation Analysis
Takeda Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Takeda Pharmaceutical Current Valuation | 70.22 B |
Most of Takeda Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Takeda Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Takeda Pharmaceutical is extremely important. It helps to project a fair market value of Takeda Stock properly, considering its historical fundamentals such as Current Valuation. Since Takeda Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Takeda Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Takeda Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Takeda Pharmaceutical Co has a Current Valuation of 70.22 B. This is 388.9% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Takeda Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in current valuation category among its peers.
Takeda Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Takeda Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Takeda Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Takeda Fundamentals
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 70.22 B | ||||
| Shares Outstanding | 3.17 B | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.26 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 900.33 B | ||||
| Net Income | 144.07 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 5.46 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,366 X | ||||
| Cash Flow From Operations | 716.34 B | ||||
| Short Ratio | 3.88 X | ||||
| Earnings Per Share | 0.60 X | ||||
| Price To Earnings To Growth | 0.70 X | ||||
| Target Price | 2471.44 | ||||
| Number Of Employees | 49.28 K | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 43.18 B | ||||
| Total Asset | 15.11 T | ||||
| Retained Earnings | 1.39 T | ||||
| Working Capital | 245.48 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 15.11 T | ||||
| Last Dividend Paid | 192.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.6 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.